GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (NYSE:BLCO) » Definitions » Total Current Liabilities

Bausch & Lomb (Bausch & Lomb) Total Current Liabilities : $1,617 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Bausch & Lomb Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Bausch & Lomb's total current liabilities for the quarter that ended in Mar. 2024 was $1,617

Bausch & Lomb Total Current Liabilities Historical Data

The historical data trend for Bausch & Lomb's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch & Lomb Total Current Liabilities Chart

Bausch & Lomb Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
Get a 7-Day Free Trial 1,035.00 909.00 1,099.00 1,296.00 1,579.00

Bausch & Lomb Quarterly Data
Dec18 Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,254.00 1,325.00 1,386.00 1,579.00 1,617.00

Bausch & Lomb Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Bausch & Lomb's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=916+30
+Other Current Liabilities+Current Deferred Liabilities
=633+0
=1,579

Bausch & Lomb's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1021+30
+Other Current Liabilities+Current Deferred Liabilities
=566+0
=1,617

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Bausch & Lomb Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Bausch & Lomb's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Bausch & Lomb (Bausch & Lomb) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (NYSE:BLCO) » Definitions » Total Current Liabilities
Comparable Companies
TSX:OPS TSXV:ZEN TSXV:OTC XCNQ:TEVO ISRG XPAR:EL BDX TSE:7741 XSWX:ALC WST OCSE:COLO B RMD TSE:4543 XSWX:STMN XPAR:DIM BAX TSE:7733 HOLX COO TSE:6869
Traded in Other Exchanges
S2L:Germany BLCO:Canada
Address
520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4
Website
https://www.bausch.com
Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Executives
Luc Bonnefoy officer: President,Surgical C/O BAUSCH + LOMB CORPORATION, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Andrew J. Stewart officer: See remarks C/O BAUSCH + LOMB CORPORATION, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Bailey A Robert D officer: EVP & Chief Legal Officer C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Brent L Saunders director, officer: CEO and Chair 2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033
Brett Icahn director C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
Gaoxiang Hu director 16690 COLLINS AVE., SUITE PH-1, SUNNY ISLES BEACH FL 33160
Bausch Health Companies Inc. 10 percent owner 2150 ST. ELZEAR BLVD. WEST, LAVAL, QUEBEC A8 H7L 4A8
Sarah B Kavanagh director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Nathalie D. Bernier director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Yehia Hashad officer: EVP, R&D and CMO C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Frederick Munsch officer: SVP, Controller and CAO C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Joseph F Gordon officer: Please see remarks C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Ross Thomas W. Sr. director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Christina Ackermann officer: Please see remarks C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Russel C Robertson director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807

Bausch & Lomb (Bausch & Lomb) Headlines

From GuruFocus

Bausch + Lomb Announces New Scientific Data and Analyses Featuring Consumer, Vision Care and Pharmaceutical Products Will Be Presented During American Optometric Association's Optometry's Meeting

By Business Wire Business Wire • 06-08-2023

Bausch + Lomb Receives FDA Approval for TENEO� Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery

By Business Wire • 01-08-2024

Bausch + Lomb Launches MIEBO� (Perfluorohexyloctane Ophthalmic Solution) in the United States

By Business Wire • 09-12-2023

Bausch + Lomb Will Participate at the 2023 Wells Fargo Healthcare Conference

By Business Wire • 08-29-2023

Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting

By Business Wire • 10-04-2023

Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA�

By Business Wire • 09-06-2023

Bausch + Lomb Reports More Than 76 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue� Eye Care Recycling Programs

By Business Wire • 11-15-2023

Bausch + Lomb to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

By Business Wire • 01-03-2024

Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA�

By Business Wire • 09-11-2023

Bausch & Lomb Corp (BLCO) Reports Q3 2023 Earnings and Raises Full-Year Guidance

By GuruFocus Research • 11-01-2023